Nuvectis Pharma (NASDAQ:NVCT) PT Raised to $21.00 at HC Wainwright

Nuvectis Pharma (NASDAQ:NVCTGet Rating) had its price target lifted by analysts at HC Wainwright from $14.00 to $21.00 in a research note issued on Tuesday, The Fly reports. HC Wainwright’s target price would indicate a potential upside of 51.62% from the stock’s previous close.

Separately, Roth Capital reiterated a “buy” rating on shares of Nuvectis Pharma in a report on Sunday, April 17th.

Nuvectis Pharma stock traded down $1.21 during trading hours on Tuesday, reaching $13.85. 508 shares of the company’s stock were exchanged, compared to its average volume of 1,438,644. The stock’s 50 day moving average price is $9.03. Nuvectis Pharma has a twelve month low of $3.08 and a twelve month high of $19.97.

In other news, CEO Ron Bentsur bought 7,000 shares of Nuvectis Pharma stock in a transaction dated Thursday, March 17th. The stock was bought at an average cost of $7.63 per share, for a total transaction of $53,410.00. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Over the last quarter, insiders have acquired 19,000 shares of company stock valued at $128,650.

Nuvectis Pharma Company Profile (Get Rating)

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of targeted small molecule therapeutics for the treatment of cancer. The company develops NXP800, an oral small molecule inhibitor of the Heat Shock Factor 1 pathway, a signaling pathway in the initiation and progression of various cancers; and NXP900 program, an oral small molecule designed to inhibit the SRC and YES1 kinases.

Featured Stories

The Fly logo

Receive News & Ratings for Nuvectis Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectis Pharma and related companies with MarketBeat.com's FREE daily email newsletter.